Patient Preferences for Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHY) in Adults with Primary Immunodeficiencies (PI): Phase 3 Study Results

被引：0
|
作者：
Ito, D. [1 ]
Ye, X. [2 ]
Xiong, Y. [1 ]
Li-McLeod, J. [1 ]
Schiff, R. [1 ]
Faivre, P. [3 ]
机构：
[1] Baxter HealthCare, Med Outcomes Res & Econ, Westlake Village, CA USA
[2] Baxter HealthCare, Med Outcomes Res & Econ, Deerfield, IL USA
[3] Baxter HealthCare, Hlth Econ & Market Access, Westlake Village, Switzerland
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
ESID-0294
引用
收藏
页码：S381 / S382
页数：2
相关论文
共 46 条
  • [31] Tolerability and safety of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immune globulin G, 10%, in patients with primary immunodeficiencies: A study from North America
    Kobayashi, R.
    Stein, M.
    Darter, A.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Fielhauer, K.
    Schiff, R. I.
    ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (03) : 298 - 298
  • [32] Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)
    Melamed, I.
    Wasserman, R. L.
    Stein, M.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB203 - AB203
  • [33] LONG-TERM SAFETY, EFFICACY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Kobrynski, L.
    Puck, J.
    Gupta, S.
    Engl, W.
    McCoy, B.
    Leibl, H.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A34 - A34
  • [34] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB15 - AB15
  • [35] INTERIM RESULTS OF A NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF SCIG 10% INFUSION FACILITATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHUPH20) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)
    Ellerbroek, Pauline
    Hanitsch, Leif
    Schmidt, Reinhold
    van Hagen, P. M.
    van Paassen, Pieter
    Borte, Michael
    Berner, Todd
    Nikolov, Nikolai
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 216 - 216
  • [36] Patient preference for subcutaneous nivolumab (NIVO) with/without recombinant human hyaluronidase PH20 (rHuPH20) vs intravenous NIVO: An exploratory analysis of a phase I/II pharmacokinetic multi-tumor study
    Lonardi, S.
    Bennett, B. M.
    Dixon, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S881 - S881
  • [37] POPULATION PHARMACOKINETIC (POPPK) SIMULATIONS TO ADDRESS TIME TO REACH STEADY STATE OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN (IG) (IGHY) IN IG-NAIVE PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
    Dumas, Todd
    Numerof, Robert
    Pierre, Vadryn
    Gelmont, David
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 272 - 272
  • [38] Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design
    LWasserman, Richard
    Leavis, Helen
    Nagy, Andras
    Carrasco, Paz
    Anderson-Smits, Colin
    McCoy, Barbara
    Bauer, Alexander
    Chu, Liang-Hui
    Freedman, Immanuel
    Li, Zhaoyang
    CLINICAL IMMUNOLOGY, 2024, 262
  • [39] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G in Patients Aged ≥18 Years with Primary Immunodeficiency Diseases
    Wasserman, Richard L.
    Stein, Mark
    Kobrynski, Lisa
    Gupta, Sudhir
    Grant, J. Andrew
    Rubinstein, Arye
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S53
  • [40] SAFETY AND TOLERABILITY OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS (IGSC), 20%: INTERIM ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
    Krivan, G.
    Gulacsy, V.
    Borte, M.
    Ganschow, R.
    Harrer, T.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Yel, L.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 137 - 137
12345